| From: donpat | 7/14/2005 11:47:35 AM | | | | | | Dr. John Rossi, Holder of 14 Key Patents, and Author of over 275 Scientific Articles, Joins NanoViricides, Inc. Scientific Advisory Board
Thursday July 14, 9:33 am ET
"Widely Regarded as a World Leader in Clinical Research for the Treatment of HIV/AIDS and in the Development of Therapeutic Applications of RNA Interference"
NEW YORK--(BUSINESS WIRE)--July 14, 2005-- NanoViricides, Inc. (Pink Sheets:NNVC - News), announced today that Dr. John Rossi, Chairman and Professor, Division of Molecular Biology, Beckman Research Institute and Dean, Graduate School of Biological Sciences, City of Hope National Medical Center, Duarte, CA
cityofhope.org
has joined the NanoViricides, Inc. Scientific Advisory Board.
City of Hope is a Comprehensive Cancer Center dedicated to the prevention and cure of cancer, HIV/AIDS, diabetes, and other life-threatening diseases.
"Dr. Rossi is a wonderful addition to our Scientific Advisory Board. He brings almost twenty five years of basic HIV research experience to our company. He is on the editorial boards of numerous science journals including Antisense Research and Development, Gene Therapy and Molecular Biology and Molecular Therapy, and has extensive experience in many critical areas that will help us develop true HIV killing nanomachines," said Eugene Seymour, MD, Chief Executive Officer of NanoViricides, Inc.
"Dr. Rossi has great expertise in the clinical aspects as well as in the HIV genome silencing aspects which are areas of special interest to NanoViricides. His active involvement as our scientific advisor will accelerate our development programs particularly for our second generation anti-HIV drugs and other nanoviricides," said Dr. Diwan, President of NanoViricides, Inc. and inventor of the underlying technology.
In addition to his responsibilities at the City of Hope, he is also Adjunct Professor, Division of Biomedical Sciences, University of California, Riverside, CA, as well as Adjunct Professor, Department of Biochemistry and Microbiology, Loma Linda University, CA.
Dr. Rossi received his PhD in microbial genetics from the University of Connecticut. His post-doctoral fellowship was at Brown University in Providence, RI.
About NanoViricides - nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types: HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a NanoViricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the NanoViricide(TM) particle, destroying it. The company plans to develop novel NanoViricide(TM) drugs first against HIV, and anticipates that it will license the products to major pharmaceutical companies.
Contact:
NanoViricides, Inc., New York
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com
or
Anil R. Diwan, Ph.D.
adiwan@snet.net
Source: NanoViricides, Inc.
biz.yahoo.com |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: donpat | 7/17/2005 3:35:26 PM | | | | | | I wonder if A DNA 'tool' could be in NNVC's future:
Researchers turn DNA into a tool
By GREG KLINE
© 2005 THE NEWS-GAZETTE
Published Online July 17, 2005
Nature uses DNA molecules to store information. For example, about making proteins our body needs to function properly.
But University of Illinois researchers are using DNA in a different way - as a construction tool.
UI chemistry Professor Scott Silverman and colleagues employ the tendency of the ribbonlike DNA molecules to take a certain shape to control the shapes of other large macromolecules well over 100 atoms in size.
Moreover, they can tell going in whether the DNA will affect the shape of the target molecule to which they attach it.
"In order to use it we have to have a reasonably firm predictive ability," Silverman said recently.
Their method, published in the Journal of the American Chemical Society by Silverman and UI graduate student Chandrasekhar Miduturu, is the result of five years of work that will end up as Miduturu's doctoral dissertation. The work has been supported by the UI and the David and Lucile Packard Foundation.
At this point, the UI-developed technique is a good basic science tool for understanding how molecules such as DNA, RNA and proteins fold and take on structures, a process that's biologically essential and on the cutting edge of biotechnology.
"Here, we're trying to understand nature," Silverman said. "The utility of all this is still to be proven."
But if scientists can understand the process, they also may be able to use the tool to control it "in ways that could be potentially useful," he said.
"The shapes of molecules affect how they function," Silverman said. "By controlling the shape we have a way to control, eventually, the function."
At least some diseases are apparently rooted in breakdowns when molecules fold. The technique might, at some point in the future, be used to fix that, although Silverman thinks it's a stretch at this point to say it will lead to medical treatments.
Likewise, molecules often get together to create tiny molecular machines with various functions. The tool could be used to shape components in such machines and assemble them.
The technique might be useful in nanotechnology with
nonbiological macromolecules, as well, for instance the polymers that make up plastics.
"I think nonbiological applications are more likely," Silverman said. "But who knows what people are going to be able to come up with if we have control ... in such a detailed manner."
Other scientists have used DNA as a static "scaffold" on which to hang molecules in an array, typically two-dimensional.
But using it dynamically, and particularly with predictable results, to control the shape of individual molecules in three dimensions is a breakthrough for Silverman's lab, which emphasizes the study of nucleic acids like DNA and RNA.
RNA macromolecules, which the body uses to transform the information stored by DNA into things like proteins, are the test subject on which the UI researchers have applied DNA as a shape controller governed by chemical reactions.
To do that, they chemically attach two strands of DNA to an unfolded RNA molecule. The DNA strands resemble two sides of a ladder cut down the middle through its rungs. Those sides naturally join to create the classic "double helix" shape of DNA molecules.
The researchers then prompt the RNA molecule to fold as much as it can. The DNA, depending on its position, length and the chemistry used, either does nothing, like a barnacle stuck to a boat hull, or influences the structure of the RNA, Silverman said.
"Something's got to give, either the structure of the macromolecule or the DNA double helix," he said. "You can have cake. You can have ice cream. But you can't have both. We can predict and control" which.
Silverman and colleagues are working on attaching more than one DNA constraint to RNA and other large molecules, which might give them, in essence, two switches that could be turned on and off to orchestrate the folding process at various stages.
"That's some place that we'd like to go," Silverman said, "to see how much control we can have."
They also plan to work on shaping molecules in ways that could potentially allow them to assemble into molecular machines.
news-gazette.com
|
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (15) | 7/17/2005 5:06:05 PM | | From: donpat | | | | OK
What I did do, the other day, was email Diwan notifying him of the two NNVC threads, one here and one at iHub. So if he isn't THAT busy, he should already be aware of it!
But I will email it, anyway. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: donpat who wrote (16) | 7/17/2005 5:14:56 PM | | From: jmhollen | | | | The email is probably the best route.
Many CEOs don't read the Boards, so they can claim "plausible deniability" if someone gets their 'nips' in the SEC wringer....
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: donpat who wrote (16) | 7/19/2005 4:12:15 AM | | From: Max2442 | | | | Donpat I received your information and am looking forward to tomorrow. I have my limit order in. As you know we have been friends long enough to trust the others judgement.
My connections come and go here so I am trusting on your DD and Jim's knowledge.
Ah another restless night and perfect for DD.
Thanks to both of you. Hopefully I will fill tomorrow along with ACHI and join the party.
TIA
Max |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: archimedest | 7/19/2005 10:38:22 AM | | | | | | | Looks like word is starting to get out as the price slowly climbs and larger blocks are being put through. Anyone know why the quotes on Pink Sheets.com don't appear? I wonder if it has anything to do with their pending move to the otc market? |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: archimedest who wrote (19) | 7/19/2005 12:49:36 PM | | From: jmhollen | | | | The same thing happened to HISC today, and the day-flippers and wienies shorted/sold causing a big dip, ...now recovering.
Per Pinksheets.com, they supposedly sent out notifications for comapnies to update their Form-211, or whatever, and if they didn't get them by yesterday they crap-canned their quotes.
I'm betting that the "..notification.." was some measley, dumbass email that was worded in a manner that got no one's attention. You might want to call NNVC and gig them about it.
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 7/19/2005 1:38:05 PM | | | | | | Purdue focuses on cancer research
11:44 AM July 19, 2005
Associated Press
Purdue University is creating a new cancer research center where scientists from wide-ranging fields will exchange ideas to develop powerful new therapies.
The Oncological Sciences Center announced today eventually will be located at Purdue’s Discovery Park research complex in West Lafayette, where faculty members work on new technologies that can be spun off into biotech companies.
The oncology center is one of four newly created Discovery Park centers that will receive $2.5 million each over the next three years under a $10 million gift from the Lilly Endowment.
Marietta Harrison, the center’s interim director, said scientists, engineers and experts in communication and human behavior will come together under its aegis to work on ideas for early detection, prevention and treatment of cancer.
A key part of the interdisciplinary approach will be nanotechnology, which involves manipulating single atoms and molecules to create tiny machines and devices.
Already, Harrison said Purdue researchers are working on projects aimed at spotting tiny tumors and distinguishing normal cells from cancer cells. Early tumor detection can allow doctors to stop cancer in patients before it spreads.
The center also will fund a nanotech project that researchers hope can use tiny, constructed “particles” that, when injected into a patient, would be capable of seeking out cancer cells and injecting them with a drug that kills them.
“You need all kinds people with different kinds of expertise to put something like that together,” Harrison said. “It’s engineers and biologists and now chemists — so you can see how hugely important the interdisciplinary approach is going to be.”
The new center’s projects will be scattered across Purdue’s campus for now, but fund-raising is under way to build a high-tech home for the center at Discovery Park, she said.
Harrison said the center’s projects might use laboratory space at the park’s Bindley Biosciences Center and the Birck Nanotechnology Center, which opens Oct. 8.
David Johnson, the chief executive of BioCrossroads, a public-private partnership working to invigorate Indiana’s life sciences industry, said the new Purdue center will spur the state’s efforts to create technology-based, high-growth businesses.
“Two years ago when we did a targeting study of the best areas for Indiana’s life sciences future, cancer research came up time and again as one of the most promising pursuits we could have as a state,” Johnson said. “Seeing Purdue come into this is very, very exciting.”
Over the past few years, Discovery Park has attracted more than $109 million in sponsored research and $100 million in donations for building construction. Research conducted at the park has helped form eight startup companies.
indystar.com |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
